Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.91 SEK | +1.11% | +1.79% | -26.02% |
06-11 | Nanexa AB Announces That First Patient Dosed in Nanexa's Phase I Trial of NEX-22 in Type 2 Diabetes | CI |
05-15 | Nanexa AB Elects Hanna Tilus as Members of the Board | CI |
- Stock Market
- Equities
- NANEXA Stock
- News Nanexa AB
- MarketScreener Editorial Features